Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. (Nasdaq: DMIIU) is a blank-check company organized to pursue an acquisition in the domestic pharmaceutical manufacturing and life sciences sector. The SPAC filed an 8-K current report with the SEC on April 28, 2026, under accession number 0001213900-26-048687. As its name indicates, the vehicle targets opportunities tied to U.S.-based drug production, a sector that has drawn sustained capital markets interest amid ongoing focus on domestic supply chain resilience. DMIIU represents the sponsor's second dedicated blank-check vehicle in this space, following the original Drugs Made In America Acquisition Corp. For complete filing history, sponsor details, and deal timeline data on DMIIU and the broader SPAC market, sign up for full access at SpacDesk.